Application of Theiler's murine encephalomyelitis virus in treatment of multiple sclerosis
Lin Li1,2,3, Rui Zhou2,3, Lin Sun1
1Third Hospital of Shanxi Medical University, Shanxi Medical University,Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.
Abstract:
Theiler's murine encephalomyelitis virus (TMEV) infected mice have been often used as an animal model for Multiple sclerosis (MS) due to their similar pathology in the central nervous system (CNS). So far, there has been no effective treatment or medicine to cure MS completely. The drugs used in the clinic can only reduce the symptoms of MS, delay its recurrence, and increase the interval between relapses. MS can be caused by many factors, and clinically MS drugs are used to treat MS regardless of what factors are caused rather than MS caused by a specific factor. This can lead to inappropriate medicine, which may be one of the reasons why MS has not been completely cured. Therefore, this review summarized the drugs investigated in the TMEV-induced disease (TMEV-IDD) model of MS, so as to provide medication guidance and theoretical basis for the treatment of virus-induced MS.
Insights
Theiler's murine encephalomyelitis virus (TMEV) infection in mice models Multiple Sclerosis (MS). This review guides treatment for virus-induced MS by summarizing drugs used in the TMEV-induced disease model.
Area of Science:
- Neuroscience
- Virology
- Immunology
Background:
- Theiler's murine encephalomyelitis virus (TMEV) infection in mice serves as a key animal model for Multiple Sclerosis (MS) due to shared central nervous system (CNS) pathology.
- Current MS treatments offer symptomatic relief and delay relapses but do not provide a complete cure, highlighting the need for more targeted therapies.
Purpose of the Study:
- To review and analyze drugs investigated within the TMEV-induced disease (TMEV-IDD) model of MS.
- To provide a medication guidance and theoretical foundation for treating virus-induced MS.
Main Methods:
- Literature review of studies utilizing the TMEV-IDD model for drug investigation.
- Analysis of therapeutic outcomes and mechanisms of action for various drugs.
Main Results:
- The TMEV-IDD model recapitulates key aspects of MS pathology, making it valuable for preclinical drug screening.
- Identified several drug candidates with potential efficacy in mitigating TMEV-induced CNS inflammation and demyelination.
Conclusions:
- The TMEV-IDD model is crucial for understanding MS pathogenesis and evaluating novel therapeutic strategies.
- Targeted treatments based on etiological factors, such as viral induction, may offer improved outcomes for MS patients.
